SCHEMBL10036128

SCHEMBL10036128

CCN1/C(=C/C=C/C=C/c2sc3c4ccccc4ccc3[n+]2CC)Sc2c1ccc1ccccc21

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT1 Q99873 9/20 0.69
PRMT5 O14744 1/20 0.61
CARM1 Q86X55 1/20 0.61
PRMT8 Q9NR22 1/20 0.61
MEN1 O00255 4/20 0.55
KMT2A Q03164 4/20 0.55
HTT P42858 3/20 0.55
BLM P54132 3/20 0.55
NPC1 O15118 3/20 0.54
RAB9A P51151 3/20 0.54
KDM4E B2RXH2 1/20 0.54
USP2 O75604 1/20 0.54
ALDH1A1 P00352 1/20 0.54
LMNA P02545 1/20 0.54
POLB P06746 1/20 0.54
GAA P10253 1/20 0.54
MAPT P10636 1/20 0.54
THRB P10828 1/20 0.54
PKM P14618 1/20 0.54
XBP1 P17861 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14509025 1.00 PRMT1 (0.69) PRMT1PRMT5CARM1PRMT8MEN1
Iodide SCHEMBL7696837 0.99 PRMT1 (0.69) PRMT1PRMT5CARM1PRMT8MEN1
Iodide SCHEMBL7696840 0.99 PRMT1 (0.69) PRMT1PRMT5CARM1PRMT8MEN1
SCHEMBL16867335 0.96 PRMT1 (0.73) PRMT1PRMT5CARM1PRMT8MEN1
SCHEMBL13222318 0.96 PRMT1 (0.73) PRMT1PRMT5CARM1PRMT8MEN1
SCHEMBL10035991 0.96 PRMT1 (0.73) PRMT1PRMT5CARM1PRMT8MEN1
Iodide SCHEMBL7908601 0.95 PRMT1 (0.73) PRMT1PRMT5CARM1PRMT8MEN1
SCHEMBL13954286 0.88 PRMT1 (0.65) PRMT1PRMT5CARM1PRMT8MEN1
Iodide SCHEMBL11688951 0.88 MEN1 (0.70) PRMT1PRMT5CARM1PRMT8MEN1
SCHEMBL10036044 0.86 PRMT1 (0.76) PRMT1PRMT5CARM1PRMT8MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120035187-A1 ANTI-NEURODEGENERATIVE DISEASE AGENT KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) 2012-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035187-A1 ANTI-NEURODEGENERATIVE DISEASE AGENT SNCA, PSEN1, CDR2 PRMT1 130/4885PRMT5 584/4885CARM1 970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.